RxDoctor Payments Data

Edward Geltman, MD

Advanced Heart Failure and Transplant Cardiology · Saint Louis, MONPI 1255357562

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (58.3%), food and beverage and education — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Pfizer at 58.3% of the total. Reporting peaked in 2020 at $2,142 and has fallen 92.0% since, to $172 in 2025. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in MO, where the typical reported total is $7,967.

$3,605in general payments, 2019–2025

Across 22 payments — averaging $163.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$2K
  • Abbott$434
  • Actelion Pharmaceuticals US, Inc.$306
  • Medtronic$242
  • Amgen$173
  • Cvrx, Inc.$129
  • plus $222 from 2 others
$121,509in research payments, 2019–2025

Across 28 payments — averaging $4339.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$42K
  • Eli Lilly$26K
  • Novartis$20K
  • Vifor (international) Ltd.$18K
  • ZOLL Respicardia, Inc.$16K

What the payments were for

  • Speaking & faculty fees$2,10058%
  • Food & beverage$1,40539%
  • Education$1003%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer1$2,100
Abbott9$434
Actelion Pharmaceuticals US, Inc.3$306
Medtronic3$242
Amgen3$173
Cvrx, Inc.1$129
Novartis1$122
AstraZeneca1$100

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,605 in reported general payments places this provider in the 30th percentile of 26 advanced heart failure and transplant cardiology providers in Missouri.

See all advanced heart failure and transplant cardiology providers in Missouri

Medicare billing

Part B allowed, 2024
$64,614
Medicare patients
352
Services billed
794

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan364$413,143
JardianceEmpagliflozin156$169,260
EliquisApixaban127$158,397
FarxigaDapagliflozin Propanediol178$154,985
XareltoRivaroxaban47$39,212
OzempicSemaglutide24$33,586
Tadalafil13$25,846
CorlanorIvabradine Hcl27$14,909
VerquvoVericiguat11$12,232
Metoprolol Succinate539$6,923
Repatha SyringeEvolocumab13$6,603
Ranolazine ErRanolazine72$5,596
Digoxin268$4,764
Bumetanide72$3,065
Eplerenone45$2,971

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$122$413,143364 claims
PfizerEliquis$2,100$158,397127 claims
AstraZenecaFarxiga$100$154,985178 claims
AmgenCorlanor$173$14,90927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 26 advanced heart failure and transplant cardiology providers in Missouri.

Other advanced heart failure and transplant cardiology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →